Patent · US Active

Anti-GDF15 antibodies

US9175076B2 · kind B2 · utility

9Cited by

15References

11Claims

0Family size

Assignee

AVEO Pharmaceuticals, Inc. · US

Inventors

Lorena Lerner · Newton, US
Sandra Abbott · Boston, US
Ailin Bai · Newton, US
Ting Chen · Austin, US
Maria Isabel Chiu · Boston, US
Qing Liu · Acton, US
Laura Poling · Boston, US
Nianjun Tao · Watertown, US
Solly Weiler · Newton, US
Zhigang Weng · Cambridge, US
William M. Winston, Jr. · Marlborough, US
Jeno Gyuris · Lincoln, US

Key dates

Filing date	Dec 20, 2013
Grant date	Nov 3, 2015
Priority date	—
Expiry date	Dec 20, 2033

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N15/63
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Monoclonal antibodies that bind and inhibit the activity of human GDF15 are disclosed. The antibodies can be used to treat body weight loss, including cachexia, associated with the over-expression of human GDF15.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.